drugset / Trial / NCT03999853
Butyrate Adjuvant Therapy for Type 1 Diabetes
Phase 1/2
Completed
6 enrolled
Mayo Clinic
BioKier Inc. · collabJuvenile Diabetes Research Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Timeline
- Start
- 2022-07-28
- Primary completion
- 2025-04-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BKR-017 | Unknown | 1.5 g | — |